rosuvastatin/ezetimibe vs sofosbuvir/velpatasvir
Side-by-side comparison of rosuvastatin/ezetimibe and sofosbuvir/velpatasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.
Recommendation: You should start with a low 5 mg dose of rosuvastatin and never take more than 10 mg daily while using this combination.
Roszet
Epclusa
Roszet contains rosuvastatin, which is a statin medicine. It helps lower bad cholesterol and reduce the risk of heart problems.
Vosevi is a drug that combines three medicines into one tablet. It is used to treat hepatitis C in adults who have already tried other treatments.
This medicine can help lower LDL cholesterol (bad cholesterol) if you have high cholesterol. It can also slow down the hardening of your arteries. Roszet can also lower triglycerides if you have high triglycerides.
Vosevi treats chronic hepatitis C (HCV) infection in adults. It is for those without cirrhosis or with compensated cirrhosis (Child-Pugh A). You can use it if you have genotype 1, 2, 3, 4, 5, or 6 HCV. You must have already been treated with a hepatitis C medicine containing an NS5A inhibitor, or sofosbuvir without an NS5A inhibitor (for genotypes 1a or 3).
Rosuvastatin blocks a substance your body needs to make cholesterol. This lowers the amount of cholesterol in your blood. It helps prevent heart attacks and strokes.
Vosevi contains sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir blocks a protein called NS5B polymerase that the hepatitis C virus needs to multiply. Velpatasvir blocks the NS5A protein, and voxilaprevir blocks the NS3/4A protease protein, both of which the virus also needs.
- • Headache
- • Nausea
- • Muscle pain
- • Weakness
- • Constipation
- • Headache
- • Fatigue (feeling tired)
- • Diarrhea
- • Nausea (feeling sick to your stomach)
- Tiredness 11,698
- Feeling sick to your stomach 10,037
- Difficulty breathing 9,212
- Loose stools 9,199
- Muscle pain 8,784
- Feeling tired 2,307
- Hepatitis C infection 1,734
- Headache 1,639
- Feeling sick to your stomach 1,386
- Low red blood cell count 1,185
Rosuvastatin can sometimes cause muscle problems, including rhabdomyolysis. This can damage your kidneys. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor may do blood tests to check your liver.
Vosevi can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Before starting Vosevi, your doctor will test you for Hepatitis B. They will also monitor you during and after treatment.
Rosuvastatin can harm your unborn baby. Do not take this medicine if you are pregnant. Breastfeeding is also not recommended while taking rosuvastatin.
It is not known if Vosevi can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Vosevi passes into breast milk, so discuss this with your doctor if you are breastfeeding.
How to Read This rosuvastatin/ezetimibe vs sofosbuvir/velpatasvir Comparison
rosuvastatin/ezetimibe is classified in the Statin / Cholesterol Absorption Inhibitor drug class, while sofosbuvir/velpatasvir sits within the NS5B/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, rosuvastatin/ezetimibe has 48,930 submissions while sofosbuvir/velpatasvir has 8,251. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to this antiviral medicine increases the amount of rosuvastatin in your system by changing how your body processes it. higher levels of the drug can increase the risk of muscle damage.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between rosuvastatin/ezetimibe and sofosbuvir/velpatasvir - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.